An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction

Abstract

Many patients with mildly reduced lvef and minimal heart failure symptoms might be able to continue trastuzumab without further decline in lvef, adverse cardiac events, or death when treated under the supervision of a cardiologist with close follow-up.